{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:46Z","timestamp":1787003806107,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer progression, biomarker identification and the design of individualized therapies. Using chronic myeloid leukemia (CML) as a paradigm for hierarchical disease evolution we show that combined population dynamic modelling and CML patient biopsy genomic analysis enables patient stratification at unprecedented resolution. Linking CD34\n                    <jats:sup>+<\/jats:sup>\n                    similarity as a disease progression marker to patient-derived gene expression entropy separated established CML progression stages and uncovered additional heterogeneity within disease stages. Importantly, our patient data informed model enables quantitative approximation of individual patients\u2019 disease history within chronic phase (CP) and significantly separates \u201cearly\u201d from \u201clate\u201d CP. Our findings provide a novel rationale for personalized and genome-informed disease progression risk assessment that is independent and complementary to conventional measures of CML disease burden and prognosis.\n                  <\/jats:p>","DOI":"10.1038\/srep24057","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T05:22:06Z","timestamp":1459920126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia"],"prefix":"10.1038","volume":"6","author":[{"given":"Marc","family":"Brehme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schuppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"BFsrep24057_CR1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong, S. & Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247\u2013306 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"BFsrep24057_CR2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20062335","volume":"204","author":"RA Van Etten","year":"2007","unstructured":"Van Etten, R. A. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J. Exp. Med. 204, 461\u2013465 (2007).","journal-title":"J. Exp. Med."},{"key":"BFsrep24057_CR3","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","volume":"106","author":"M Brehme","year":"2009","unstructured":"Brehme, M. et al. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106, 7414\u20137419 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep24057_CR4","first-page":"8","volume":"13","author":"C Fausel","year":"2007","unstructured":"Fausel, C. Targeted chronic myeloid leukemia therapy: seeking a cure. J. Manag. Care Pharm. JMCP 13, 8\u201312 (2007).","journal-title":"J. Manag. Care Pharm. JMCP"},{"key":"BFsrep24057_CR5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama, A. & Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619\u20131630 (2009).","journal-title":"Blood"},{"key":"BFsrep24057_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4065\/84.2.161","volume":"84","author":"E Jabbour","year":"2009","unstructured":"Jabbour, E., Cortes, J. E. & Kantarjian, H. M. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin. Proc. 84, 161\u2013169 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFsrep24057_CR7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani, M. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108, 1809\u20131820 (2006).","journal-title":"Blood"},{"key":"BFsrep24057_CR8","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani, M. et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041\u20136051 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFsrep24057_CR9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal, J. E. et al. Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia. Blood 63, 789\u2013799 (1984).","journal-title":"Blood"},{"key":"BFsrep24057_CR10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford, J. et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl. Cancer Inst. 90, 850\u2013858 (1998).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFsrep24057_CR11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford, J. et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118, 686\u2013692 (2011).","journal-title":"Blood"},{"key":"BFsrep24057_CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon, F.-X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"BFsrep24057_CR13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","volume":"95","author":"D Milojkovic","year":"2010","unstructured":"Milojkovic, D. et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95, 224\u2013231 (2010).","journal-title":"Haematologica"},{"key":"BFsrep24057_CR14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267\u20131270 (2005).","journal-title":"Nature"},{"key":"BFsrep24057_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLK.2008.n.017","volume":"2","author":"D Dingli","year":"2008","unstructured":"Dingli, D., Traulsen, A. & Pacheco, J. M. Chronic Myeloid Leukemia: Origin, Development, Response to Therapy and Relapse. Clin. Leuk. 2, 133\u2013139 (2008).","journal-title":"Clin. Leuk."},{"key":"BFsrep24057_CR16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder, I. et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12, 1181\u20131184 (2006).","journal-title":"Nat. Med"},{"key":"BFsrep24057_CR17","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich, J. P. et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 103, 2794\u20132799 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep24057_CR18","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","volume":"114","author":"VG Oehler","year":"2009","unstructured":"Oehler, V. G. et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 114, 3292\u20133298 (2009).","journal-title":"Blood"},{"key":"BFsrep24057_CR19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature12831","volume":"504","author":"B Haibe-Kains","year":"2013","unstructured":"Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389\u2013393 (2013).","journal-title":"Nature"},{"key":"BFsrep24057_CR20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1755-8794-4-73","volume":"4","author":"S Schneckener","year":"2011","unstructured":"Schneckener, S., Arden, N. S. & Schuppert, A. Quantifying stability in gene list ranking across microarray derived clinical biomarkers. BMC Med. Genomics 4, 73 (2011).","journal-title":"BMC Med. Genomics"},{"key":"BFsrep24057_CR21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano, J. A. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med. 373, 2005\u20132014 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep24057_CR22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","volume":"122","author":"K Cramer-Morales","year":"2013","unstructured":"Cramer-Morales, K. et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122, 1293\u20131304 (2013).","journal-title":"Blood"},{"key":"BFsrep24057_CR23","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1038\/sj.leu.2401281","volume":"13","author":"MY Gordon","year":"1999","unstructured":"Gordon, M. Y. et al. Cell biology of CML cells. Leukemia 13 Suppl 1, S65\u201371 (1999).","journal-title":"Leukemia"},{"key":"BFsrep24057_CR24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","volume":"16","author":"AS Shet","year":"2002","unstructured":"Shet, A. S., Jahagirdar, B. N. & Verfaillie, C. M. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16, 1402\u20131411 (2002).","journal-title":"Leukemia"},{"key":"BFsrep24057_CR25","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1371\/journal.pone.0000345","volume":"2","author":"D Dingli","year":"2007","unstructured":"Dingli, D., Traulsen, A. & Pacheco, J. M. Compartmental architecture and dynamics of hematopoiesis. PloS One 2, e345 (2007).","journal-title":"PloS One"},{"key":"BFsrep24057_CR26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759\u2013771 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"BFsrep24057_CR27","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda, B. & Melo, J. V. Natural course and biology of CML. Ann. Hematol. 94 Suppl 2, S107\u2013121 (2015).","journal-title":"Ann. Hematol."},{"key":"BFsrep24057_CR28","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie, E. et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121, 4175\u20134183 (2013).","journal-title":"Blood"},{"key":"BFsrep24057_CR29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFsrep24057_CR30","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012).","journal-title":"Blood"},{"key":"BFsrep24057_CR31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.bjc.6603310","volume":"95","author":"LH Abbott","year":"2006","unstructured":"Abbott, L. H. & Michor, F. Mathematical models of targeted cancer therapy. Br. J. Cancer 95, 1136\u20131141 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFsrep24057_CR32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603603","volume":"96","author":"I Glauche","year":"2007","unstructured":"Glauche, I., Horn, M. & Roeder, I. Leukaemia stem cells: hit or miss? Br. J. Cancer 96, 677\u2013678; author reply 679\u2013680 (2007).","journal-title":"Br. J. Cancer"},{"key":"BFsrep24057_CR33","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/bjc.2012.142","volume":"106","author":"I Glauche","year":"2012","unstructured":"Glauche, I. et al. Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations. Br. J. Cancer 106, 1742\u20131752 (2012).","journal-title":"Br. J. Cancer"},{"key":"BFsrep24057_CR34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner, R. S. et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27, 671\u2013681 (2015).","journal-title":"Cancer Cell"},{"key":"BFsrep24057_CR35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"BFsrep24057_CR36","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti, D., Jamieson, C., Goldman, J. & Skorski, T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 120, 2254\u20132264 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFsrep24057_CR37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid. Leukemia 23, 1054\u20131061 (2009).","journal-title":"Leukemia"},{"key":"BFsrep24057_CR38","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.V95.6.1883","volume":"95","author":"TH Br\u00fcmmendorf","year":"2000","unstructured":"Br\u00fcmmendorf, T. H. et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95, 1883\u20131890 (2000).","journal-title":"Blood"},{"key":"BFsrep24057_CR39","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/leu.2014.95","volume":"28","author":"M Braig","year":"2014","unstructured":"Braig, M. et al. A \u2018telomere-associated secretory phenotype\u2019 cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia 28, 2028\u20132039 (2014).","journal-title":"Leukemia"},{"key":"BFsrep24057_CR40","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1634\/stemcells.2007-0057","volume":"25","author":"MW Drummond","year":"2007","unstructured":"Drummond, M. W., Balabanov, S., Holyoake, T. L. & Brummendorf, T. H. Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells. STEM CELLS 25, 1853\u20131861 (2007).","journal-title":"STEM CELLS"},{"key":"BFsrep24057_CR41","doi-asserted-by":"crossref","unstructured":"Haken, H. Synergetics: An introduction: nonequilibrium phase transitions and self-organization in physics, chemistry and biology. (Springer-Verlag, 1978).","DOI":"10.1007\/978-3-642-96469-5"},{"key":"BFsrep24057_CR42","first-page":"e421702","volume":"2012","author":"L Farnault","year":"2012","unstructured":"Farnault, L. et al. Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. J. Immunol. Res. 2012, e421702 (2012).","journal-title":"J. Immunol. Res."},{"key":"BFsrep24057_CR43","doi-asserted-by":"crossref","first-page":"e77627","DOI":"10.1371\/journal.pone.0077627","volume":"8","author":"M Lenz","year":"2013","unstructured":"Lenz, M., Schuldt, B. M., M\u00fcller, F.-J. & Schuppert, A. PhysioSpace: Relating Gene Expression Experiments from Heterogeneous Sources Using Shared Physiological Processes. PLoS ONE 8, e77627 (2013).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep24057","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:08:18Z","timestamp":1672841298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep24057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,26]]}},"alternative-id":["BFsrep24057"],"URL":"https:\/\/doi.org\/10.1038\/srep24057","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]},"assertion":[{"value":"28 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS is a part-time employee at Bayer Technology Services GmbH. Bayer Technology Services GmbH provides Technology Services in the field of PBPK modelling and has currently no activities in the area of disease modelling in leukemia.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24057"}}